Angermayer Christian — SEC insider filings

SEC reporting owner CIK 1845872. 39 insider filings on record with FilingPulse; latest filed 2026-09-21.

Transaction summary — filings shown

Covers all 39 filings on record, filed 2021-06-24 to 2026-09-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ATAI Life Sciences N.V. (ATAI)Director, 10% owner2419 legs · 23,838,012 sh · $59,364,795—14
Enhanced Group Inc. (ENHA)Director, 10% owner811 legs · 8,510,183 sh · $11,050,879—7
Sensei Biotherapeutics, Inc. (SNSE)10% owner22 legs · 2,200 sh · $3,5392 legs · 3,441,661 sh · $5,437,824—
BIONOMICS LTD/ADR (BNOX)10% owner1—3 legs · 272,070 sh · $82,527—
AtaiBeckley Inc. (ATAI)Director, 10% owner3——17
Alto Neuroscience, Inc. (ANRO)—1——6

Insider filings — Angermayer Christian

FiledFormIssuerReported transactionsSource
2026-09-214Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Purchase (P): 6,080,047 @ $1.15EDGAR
2026-09-114AtaiBeckley Inc. (ATAI)
jointly with Apeiron Investment Group Ltd.
Disposition to issuer (D): 559,232 · Disposition to issuer (D): 53,398,214 · Disposition to issuer (D): 1,799,302 · Disposition to issuer (D): 624,000 (derivative) · Disposition to issuer (D): 64,000 (derivative) · Disposition to issuer (D): 17,930 (derivative) · +4 moreEDGAR
2026-09-094Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Purchase (P): 21,034 @ $1.61 · Purchase (P): 59,337 @ $1.57 · Purchase (P): 99,342 @ $1.60EDGAR
2026-09-044Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Purchase (P): 107,693 @ $1.58 · Purchase (P): 25,414 @ $1.58EDGAR
2026-08-204Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Grant/award (A): 2,120,823 · Purchase (P): 93,000 @ $1.70 · Purchase (P): 1,619,316 @ $1.66 · Purchase (P): 55,000 @ $1.64 · Grant/award (A): 2,120,823 (derivative)EDGAR
2026-08-184Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Purchase (P): 200,000 @ $1.65EDGAR
2026-08-174Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Purchase (P): 150,000 @ $1.97EDGAR
2026-07-244Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Grant/award (A): 3,020,565 · Grant/award (A): 3,020,565 (derivative)EDGAR
2026-06-084AtaiBeckley Inc. (ATAI)Grant/award (A): 121,968 (derivative) @ $0EDGAR
2026-05-114Enhanced Group Inc. (ENHA)
jointly with Apeiron Investment Group Ltd., Enhanced Holdings LP
Grant/award (A): 29,692,247 · Grant/award (A): 258,837,933 · Grant/award (A): 212,499 (derivative)EDGAR
2026-04-104AtaiBeckley Inc. (ATAI)
jointly with Apeiron Investment Group Ltd.
Option exercise (M): 46,070 @ $1.88 · Option exercise (M): 410,162 @ $1.64 · Option exercise (M): 103,000 @ $1.34 · Option exercise (M): 46,070 (derivative) @ $0 · Option exercise (M): 410,162 (derivative) @ $0 · Option exercise (M): 103,000 (derivative) @ $0EDGAR
2025-10-024ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Conversion (C): 2,367,200 · Conversion (C): 147,950 (derivative)EDGAR
2025-08-184ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 8,675,799 @ $2.19EDGAR
2025-06-274ATAI Life Sciences N.V. (ATAI)Grant/award (A): 103,000 (derivative) @ $0EDGAR
2025-06-044ATAI Life Sciences N.V. (ATAI)Grant/award (A): 131,698 (derivative)EDGAR
2025-03-244ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 1,800,000 @ $1.40EDGAR
2025-02-194ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 10,835,718 @ $2.10EDGAR
2024-10-074BIONOMICS LTD/ADR (BNOX)
jointly with Apeiron Investment Group Ltd., Apeiron Presight Capital Fund II, L.P.
Sale (S): 90,806 @ $0.33 · Sale (S): 180,707 @ $0.29 · Sale (S): 557 @ $0.28EDGAR
2024-10-044ATAI Life Sciences N.V. (ATAI)Disposition to issuer (D): 624,000 (derivative) · Grant/award (A): 624,000 (derivative)EDGAR
2024-06-144ATAI Life Sciences N.V. (ATAI)Grant/award (A): 103,000 (derivative) @ $0EDGAR
2024-04-174ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Other (J): 147,950 (derivative) · Other (J): 147,950 (derivative)EDGAR
2024-03-064Alto Neuroscience, Inc. (ANRO)
jointly with Apeiron Investment Group Ltd., Apeiron Presight Capital Fund II, L.P.
Conversion (C): 251,881 · Conversion (C): 674,658 · Conversion (C): 444,561 (derivative) · Conversion (C): 406,072 (derivative) · Conversion (C): 1,063,918 (derivative) · Conversion (C): 416,665 (derivative)EDGAR
2024-01-094ATAI Life Sciences N.V. (ATAI)Grant/award (A): 642,000 (derivative) @ $0EDGAR
2023-06-024Sensei Biotherapeutics, Inc. (SNSE)
jointly with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Co-Invest Management, L.L.C.
Sale (S): 2,485,923 @ $1.58 · Sale (S): 955,738 @ $1.58EDGAR
2023-05-254ATAI Life Sciences N.V. (ATAI)Grant/award (A): 64,000 (derivative) @ $0EDGAR
2023-03-294ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 1,214,297 @ $1.32EDGAR
2023-02-274Sensei Biotherapeutics, Inc. (SNSE)
jointly with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Co-Invest Management, L.L.C.
Purchase (P): 1,100 @ $1.61 · Purchase (P): 1,100 @ $1.60EDGAR
2022-05-274ATAI Life Sciences N.V. (ATAI)Grant/award (A): 64,000 (derivative) @ $0EDGAR
2022-05-034ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 67,703 @ $5.09 · Purchase (P): 68,688 @ $4.95EDGAR
2022-05-024ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 34,700 @ $4.46 · Purchase (P): 21,900 @ $4.47EDGAR
2022-04-284ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 46,207 @ $4.69 · Purchase (P): 19,803 @ $4.64EDGAR
2022-04-264ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 52,820 @ $4.83 · Purchase (P): 8,961 @ $4.78EDGAR
2022-04-204ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 54,322 @ $5.11 · Purchase (P): 65,315 @ $5.12EDGAR
2022-04-184ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 4,967 @ $5.19EDGAR
2022-04-144ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 55,197 @ $4.88EDGAR
2022-04-124ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 57,689 @ $4.81 · Purchase (P): 53,926 @ $4.83EDGAR
2022-04-074ATAI Life Sciences N.V. (ATAI)
jointly with Apeiron Investment Group Ltd.
Purchase (P): 1,000,000 (derivative) @ $0.96EDGAR
2021-09-134ATAI Life Sciences N.V. (ATAI)Grant/award (A): 128,000 (derivative) @ $0EDGAR
2021-06-244ATAI Life Sciences N.V. (ATAI)Purchase (P): 700,000 @ $15EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-06-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1845872 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs